OA Drug Selection for This Patient - With Comorbidities

Why This Patient is High-Risk for Standard OA Drugs

Recommended Treatment Approach (Step-Up)

Step 1 - First-Line (Safest given comorbidities)

• Dose: 500-1000 mg orally every 6-8 hours, maximum 3000 mg/day (reduce to this ceiling due to age and DM risk; standard max is 4000 mg/day but 3 g/day is safer in elderly)
• No cardiovascular risk
• No effect on blood pressure or renal prostaglandins
• Safe with insulin
• Avoid if hepatic disease (none documented here)

Textbook of Family Medicine 9e confirms: "First-line pharmacologic therapies for symptom control include acetaminophen, up to 1000 mg four times daily in the absence of liver disease."

Step 2 - Topical NSAID (Preferred over systemic in this patient)

• Dose: Apply 2-4 g to affected knee 4 times daily (QID)
• Local action with minimal systemic absorption = significantly lower cardiovascular, renal, and GI risk compared to oral NSAIDs
• This is the preferred choice over systemic NSAIDs in elderly patients with ischemic cardiomyopathy and hypertension
• Especially appropriate for knee OA (as in this patient)

Step 3 - If above insufficient: Tramadol (weak opioid analgesic)

• Dose: Start at 50 mg orally once or twice daily; can be titrated up to 200 mg/day in divided doses
• No cardiovascular risk
• No effect on blood pressure
• Safe with cardiac comorbidities
• Caution: Risk of hypoglycemia with sulphonylureas (patient is on insulin - monitor closely); may lower seizure threshold; start low in elderly

Textbook of Family Medicine 9e notes: "The addition of tramadol (Ultram, 200 mg/day) in patients responding to naproxen has been shown to allow a significant reduction in the NSAID dose needed without compromising pain relief."

Step 4 - Intraarticular Injection (Adjunct)

• Frequency: Up to 4 injections per joint per year
• Provides short-term relief especially useful given this patient's knee effusion
• Caution in T2DM: Intraarticular steroids can temporarily raise blood glucose for 24-72 hours - inform patient and monitor
• Good option here because systemic NSAID risks are high

Adjunct - Glucosamine Sulfate

• Dose: 1500 mg/day (glucosamine sulfate form - not HCl)
• Studies show modest reduction in joint space narrowing and symptom improvement over 3 years
• No cardiovascular, renal, or glycemic concerns
• Safe to use alongside other agents

Drugs to AVOID in This Patient

Summary Prescription

• Textbook of Family Medicine 9e, p. 873-876

• The same drug serves multiple conditions - ACE inhibitor (Ramipril) covers both hypertension AND ischemic cardiomyopathy AND diabetic nephroprotection
• Empagliflozin covers both T2DM AND ischemic cardiomyopathy (heart failure prevention) in one tablet - per ADA 2025 this is prioritized
• Beta-blocker (Bisoprolol) covers both hypertension AND ischemic cardiomyopathy
• Paracetamol covers both OA pain AND cervical spondylosis pain
• This means despite 6 conditions, the actual number of drugs is manageable (~8-9 core agents)

• eGFR and potassium before starting ACEi + SGLT2i (risk of AKI and hyperkalemia together)
• Blood glucose after any corticosteroid injection (OA) or steroid course (cervical spine)
• Beta-blocker masking hypoglycemia - teach patient to rely on sweating rather than tremor as the hypoglycemia signal
• Gabapentin in a 65-year-old = fall risk - start at the lowest dose (100 mg nocte) and titrate slowly

Rationale for Every Drug in This Patient

Patient Reminder: Mr. Vu Dinh Ta, 65M

• Bilateral knee OA (right > left, with effusion)
• T2DM x 10 years, on insulin
• Ischemic cardiomyopathy (ECG: possible prior MI)
• Hypertension (BP 160/80 on admission)
• Dyslipidemia
• Cervical spondylosis C4-C7 with radiculopathy + bilateral hand numbness

1. OSTEOARTHRITIS DRUGS

Paracetamol (Acetaminophen) 500-1000 mg q6-8h

• He has pain 3/10 while walking - needs baseline analgesia
• Cannot use systemic NSAIDs because of ischemic cardiomyopathy (NSAIDs increase cardiovascular events and precipitate heart failure), hypertension (NSAIDs raise BP and blunt antihypertensives), and T2DM with possible renal involvement (NSAIDs impair renal prostaglandins)
• Paracetamol has zero cardiovascular risk, does not raise BP, and does not affect renal function
• First-line by every OA guideline precisely because of this safety profile

Topical Diclofenac 1% gel (applied to knee 4x/day)

• His knee OA is localized - topical delivery targets exactly where he needs it
• Because systemic absorption is minimal, it avoids the cardiovascular, renal, and blood pressure harms of oral NSAIDs
• Provides local anti-inflammatory effect (reduces prostaglandin-driven joint inflammation and effusion) that paracetamol alone cannot achieve
• This is why OARSI guidelines specifically recommend topical NSAIDs over oral NSAIDs in patients with cardiac or renal comorbidities

Tramadol 50-100 mg q12h (add-on)

• For breakthrough pain when paracetamol + topical diclofenac are insufficient
• His pain is 3/10 while walking and he cannot squat - functional limitation suggests analgesia needs to be adequate for rehabilitation
• No cardiovascular risk, no effect on blood pressure, no renal toxicity
• Avoids the harms of stronger opioids (dependency, respiratory depression)
• Particularly useful as a bridge while physiotherapy builds quadriceps strength

Intraarticular Triamcinolone 40 mg (up to 4x/year)

• He has visible joint effusion in the right knee - this is active synovitis/inflammation that oral paracetamol alone will not resolve
• Intraarticular route delivers maximum anti-inflammatory effect directly to the joint without systemic corticosteroid side effects
• In a patient with T2DM + cardiovascular disease, systemic steroids are risky - the intraarticular route localizes the drug
• Important: Even intraarticular steroids can raise blood glucose for 24-72 hours in T2DM patients - this is why monitoring was flagged

Glucosamine Sulfate 1500 mg once daily

• He has been symptomatic for 9 months with progressive joint space destruction
• Glucosamine sulfate (not HCl) has shown modest reduction in knee joint space narrowing over 3 years
• No drug interactions with any of his other medications
• No cardiovascular, renal, or glycemic effects
• Acts as a disease-modifying adjunct - not just symptom relief

2. TYPE 2 DIABETES DRUGS

Metformin 500-1000 mg twice daily

• He has had T2DM for 10 years - metformin remains the backbone of T2DM therapy
• Weight neutral - important in a 65-year-old with cardiovascular disease where obesity worsens outcomes
• Does not cause hypoglycemia on its own
• Has modest cardiovascular benefit (UKPDS trial)
• Caution: Must check eGFR. If eGFR < 30 mL/min - stop it (risk of lactic acidosis). If eGFR 30-45 - reduce dose.

Empagliflozin (SGLT2 inhibitor) 10 mg once daily

• He has established cardiovascular disease (ischemic cardiomyopathy) - EMPA-REG OUTCOME trial showed empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35% in T2DM patients with established CVD
• ADA 2025 specifically mandates SGLT2i for T2DM with established CVD, irrespective of HbA1c
• Also lowers blood pressure by 3-5 mmHg (osmotic diuresis) - beneficial for his hypertension
• Reduces body weight slightly
• Has renal protective effects
• This drug is doing triple duty - treating DM, protecting his heart, and reducing his BP

Basal Insulin (Glargine/Degludec - continue current)

• He is already on it. After 10 years of T2DM, he likely has significant beta-cell failure - insulin is necessary
• Provides the glycemic control that oral agents alone cannot achieve at this stage
• Target fasting glucose: 80-130 mg/dL (HbA1c < 7-7.5%)

3. HYPERTENSION DRUGS

Ramipril (ACE inhibitor) - start 2.5 mg → target 10 mg once daily

1. Hypertension - first-line antihypertensive, particularly in DM + cardiac patients
2. Diabetic nephroprotection - ACEi reduce proteinuria and slow diabetic nephropathy progression in T2DM
3. Ischemic cardiomyopathy - ACEi reduce cardiac remodeling after MI and reduce mortality in reduced LVEF
4. Heart failure prevention - reduces risk of HF progression

• In a patient with this many comorbidities, Ramipril is the single most efficient drug - it addresses all simultaneously
• ACC/AHA Class I recommendation for all three of his indications

Amlodipine (CCB) 5-10 mg once daily

• His BP was 160/80 on admission - a single drug (ACEi alone) likely will not achieve the target of < 130/80 mmHg
• Two-drug combination is typically needed for Stage 2 hypertension (> 160 mmHg systolic)
• Amlodipine is metabolically neutral - does not worsen blood glucose or lipids (unlike thiazides)
• No effect on heart rate (unlike beta-blockers, which could complicate his DM)
• ACC/AHA 2025: ACEi + CCB is the preferred combination for hypertension with DM and CVD

Bisoprolol (Beta-blocker) 2.5-5 mg → target dose once daily

• His ECG shows possible prior MI with left mid-axis deviation - ACC/AHA 2023 CCD guideline gives a Class I recommendation for beta-blockers in CCD with LVEF ≤ 50%
• Bisoprolol specifically (along with carvedilol and sustained-release metoprolol succinate) is one of only 3 beta-blockers proven in RCTs to reduce mortality in ischemic cardiomyopathy
• Reduces risk of re-infarction
• Controls heart rate (his HR was 93 bpm on admission - beta-blocker will bring this to 60-70 bpm target)
• Note: Being cardioselective (beta-1 only), bisoprolol is safer in diabetics than non-selective beta-blockers because it has less effect on insulin-mediated hypoglycemia recovery

4. DYSLIPIDEMIA DRUGS

Atorvastatin 40-80 mg once daily (HIGH intensity)

• He has established ASCVD (ischemic cardiomyopathy) - this automatically classifies him as very high cardiovascular risk
• ACC/AHA 2018 Cholesterol Guidelines mandate high-intensity statin (atorvastatin 40-80 mg) for all patients with established ASCVD
• Statins do far more than lower cholesterol - they stabilize atherosclerotic plaques (prevent plaque rupture = prevent MI), reduce vascular inflammation, and improve endothelial function
• LDL-C target: < 70 mg/dL (ACC/AHA) - ideally < 55 mg/dL (ESC 2019 for very high-risk CVD)
• He is already on treatment for dyslipidemia per his records - confirm he is on a high-intensity dose

Ezetimibe 10 mg once daily (add-on if needed)

• If atorvastatin alone does not bring LDL-C to target (< 70 mg/dL), ezetimibe adds a further 15-20% LDL reduction
• The IMPROVE-IT trial showed ezetimibe added to statin reduced CV events in high-risk patients
• No muscle toxicity, no hepatotoxicity - safe to add
• No interaction with insulin or his other drugs

5. CERVICAL SPONDYLOSIS DRUGS

Gabapentin 100-300 mg nocte → titrate to 300 mg three times daily

• He has bilateral finger numbness and tingling, neck pain radiating to both arms, and diagnosed C4-C7 compression with radiculopathy
• This is neuropathic pain (nerve root compression) - paracetamol and NSAIDs target nociceptive pain but are less effective for neuropathic pain
• Gabapentin is specifically indicated for radicular/neuropathic pain - it targets the abnormal nerve signaling at the compressed root level
• Systemic NSAIDs (the other option) are contraindicated in this patient due to cardiac/renal risk
• Start low (100 mg at night) because he is 65 - elderly patients are more sensitive to CNS side effects (dizziness, sedation, fall risk)

Methylprednisolone Dose Pack (for acute cervical flares only)

• When cervical radiculopathy acutely flares, rapid reduction of nerve root inflammation with 5-7 days of oral steroids can dramatically reduce pain and restore function faster
• Short-term use only - the risk of prolonged corticosteroids (hyperglycemia in T2DM, hypertension, immune suppression) makes this a targeted acute tool, not ongoing therapy
• Monitor blood glucose carefully for 72 hours after any steroid course

6. ISCHEMIC CARDIOMYOPATHY - ADDITIONAL DRUG

Aspirin 75-100 mg once daily

• He has ischemic cardiomyopathy - this means atherosclerotic coronary artery disease with prior ischemic damage to the myocardium
• Aspirin is a Class I recommendation for secondary prevention in all patients with established coronary artery disease
• Prevents platelet-driven thrombus formation on atheromatous plaques → reduces risk of future MI or acute coronary syndrome
• Low dose (75-100 mg) is as effective as high dose for secondary prevention but with significantly less GI bleeding risk

One-Line Summary of Each Drug's "WHY"